Literature DB >> 11245271

VEGF in brain tumors.

M R Machein1, K H Plate.   

Abstract

Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis, vasculogenesis and vascular permeability. In this contribution, molecular and biological properties of VEGF are described. Furthermore, this article focuses on the evidence that angiogenesis in brain tumors is mediated by VEGF. Among the topics discussed are expression patterns of VEGF and its receptors in different brain tumors, possible regulatory mechanism involved in the VEGF-driven tumor angiogenesis and the involvement of VEGF in the genesis of peritumoral edema. Finally, anti-angiogenesis approaches to target VEGF/VEGF receptors are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11245271     DOI: 10.1023/a:1006416003964

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  124 in total

1.  Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones.

Authors:  V Speirs; E Boyle-Walsh; W D Fraser
Journal:  Int J Cancer       Date:  1997-09-04       Impact factor: 7.396

2.  Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas.

Authors:  C Christov; E Lechapt-Zalcman; H Adle-Biassette; S Nachev; R K Gherardi
Journal:  Acta Neuropathol       Date:  1999-10       Impact factor: 17.088

3.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

Authors:  L E Benjamin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.

Authors:  P Lin; S Sankar; S Shan; M W Dewhirst; P J Polverini; T Q Quinn; K G Peters
Journal:  Cell Growth Differ       Date:  1998-01

5.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

Review 6.  The biology of meningiomas.

Authors:  D A Smith; D W Cahill
Journal:  Neurosurg Clin N Am       Date:  1994-04       Impact factor: 2.509

7.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

8.  Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.

Authors:  K H Plate; G Breier; C L Farrell; W Risau
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

9.  Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis.

Authors:  J Strugar; D Rothbart; W Harrington; G R Criscuolo
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

10.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.

Authors:  E Kukk; A Lymboussaki; S Taira; A Kaipainen; M Jeltsch; V Joukov; K Alitalo
Journal:  Development       Date:  1996-12       Impact factor: 6.868

View more
  67 in total

1.  The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Authors:  AeRang Kim; Cindy McCully; Rafael Cruz; Diane E Cole; Elizabeth Fox; Frank M Balis; Brigitte C Widemann
Journal:  Invest New Drugs       Date:  2010-11-12       Impact factor: 3.850

2.  Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.

Authors:  U Löbel; S Hwang; A Edwards; Y Li; X Li; A Broniscer; Z Patay
Journal:  Neuroradiology       Date:  2016-07-20       Impact factor: 2.804

3.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; Carlos J da Silva; Alberto A Gabbai; Fernando A P Ferraz; João N Stávale
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 4.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 5.  Neuroimaging in neuro-oncology.

Authors:  Soonmee Cha
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 6.  Blood-brain barrier breakdown in septic encephalopathy and brain tumours.

Authors:  D C Davies
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

7.  The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  J Cell Commun Signal       Date:  2013-03-15       Impact factor: 5.782

8.  Solid haemangioblastomas of the CNS: a review of 17 consecutive cases.

Authors:  Jens Rachinger; Rolf Buslei; Julian Prell; Christian Strauss
Journal:  Neurosurg Rev       Date:  2008-09-20       Impact factor: 3.042

9.  Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.

Authors:  Nadja Osterberg; Napoleone Ferrara; Jean Vacher; Simone Gaedicke; Gabriele Niedermann; Astrid Weyerbrock; Soroush Doostkam; Hans-Eckart Schaefer; Karl H Plate; Marcia Regina Machein
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

10.  Spatial expression of VEGF-A in human glioma.

Authors:  Mikael Johansson; Thomas Brännström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.